ArticleChinese medicine2026
Total flavonoids of Rhizoma drynariae targets NRF2-mediated anti-ferroptosis in osteoblasts to promote induced membrane osteogenesis.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundInduced membrane technique (IMT), a novel approach for reconstructing critical-size bone defect, encounters the challenge of lengthy mineralization time after bone grafting. Total flavonoids of Rhizoma drynariae (TFRD), the extracts from dried rhizome of Drynaria roosii Nakaike, is widely used in the treatment of orthopedic diseases. PURPOSE: This study primarily investigates the impact of TFRD on the NRF2-mediated anti-ferroptosis effect in osteoblasts within the IMT bone grafting area.
methodsAn IMT model was established in the right femur of rats. After 4 and 8 weeks of treatment with TFRD and DMF (an NRF2 activator) respectively, bone defect repair and ferroptosis-related indicators were evaluated. In vitro, an Erastin-induced ferroptosis model of osteoblasts was constructed to analyze the mineralization capacity of osteoblasts, ferroptosis-related indicators, and factors related to the NRF2/ARE pathway under TFRD and DMF treatment. Additionally, the components of TFRD and TFRD-containing serum were analyzed using UHPLC-Q-Orbitrap HRMS. Finally, the main compounds in TFRD that bind to the NRF2 protein were studied through molecular docking, molecular dynamics simulation (MDS), and CETSA.
resultsIn vivo results demonstrated that excessive iron accumulation occurred in the IMT bone grafting area, accompanied by elevated levels of lipid peroxidation products (MDA and 4-HNE) and decreased levels of antioxidants (GSH), suggesting the presence of ferroptosis during the bone graft mineralization process in IMT. Treatment with TFRD and DMF reduced iron accumulation and the production of MDA and 4-HNE, accelerated bone defect healing, and enhanced expression of osteogenesis-related factors and NRF2/ARE pathway factors. In vitro experiments revealed that Erastin induced ferroptosis in osteoblasts, diminishing cell viability and mineralization capacity. Treatment with TFRD and DMF alleviated mitochondrial damage, reduced production of ROS, MDA and 4-HNE, increased the expression of osteogenesis-related factors, upregulated the NRF2/ARE pathway, and enhanced cell viability and mineralization. Meanwhile, five active components in TFRD and TFRD-containing serum were identified using UHPLC-Q-Orbitrap HRMS. Molecular docking, MDS and CETSA results indicated that the main compounds in TFRD-containing serum could directly bind to the NRF2 protein in osteoblasts and maintain its stability.
conclusionThe NRF2-mediated anti-ferroptosis effect in osteoblasts positively regulated the mineralization of osteoblasts. The main components of TFRD targeted NRF2 in osteoblasts within the IMT bone grafting area, maintained its stability, promoted the expression of downstream antioxidant response elements (ARE), enhanced the anti-ferroptosis role of osteoblasts, thereby accelerating the repair of bone defects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.